Vanda Pharmaceuticals (VNDA) has risen sharply, recording gains of 27.56% in the past 4 weeks. However, the stock has corrected -1.83% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 30.2% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.24% and the 50-Day Moving Average is 19.89%.The 200 Day SMA reached 55.1% Vanda Pharmaceuticals, Inc. is up 43.19% in the last 3-month period. Year-to-Date the stock performance stands at 67.02%.
Vanda Pharmaceuticals (VNDA) : The highest level Vanda Pharmaceuticals (VNDA) is projected to reach is $24 for the short term and the lowest estimate is at $15. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $20 and the possibility the share price can swing is $3.92.
For the current week, the company shares have a recommendation consensus of Buy. Vanda Pharmaceuticals (NASDAQ:VNDA): stock was range-bound between the intraday low of $15.49 and the intraday high of $15.9 after having opened at $15.7 on Fridays session. The stock finally closed in the red at $15.7, a loss of -1.14%. The stock remained in the red for the whole trading day. The total traded volume was 1,097,237 shares. The stock failed to cross $15.9 in Fridays trading. The stocks closing price on Thursday was $15.55.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.